ArticleBMC gastroenterology2025
A serum TNFR2-based model effectively predicates preoperative microvascular invasion and stratifies the tumor recurrence risk in hepatocellular carcinoma.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Novel nanobody-161 binds tumor necrosis factor receptor 2 (TNFR2) to exert an anti-tumor effect but does not block TNFα-binding.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
aimMicrovascular invasion (MVI) is a key risk factor for hepatocellular carcinoma (HCC) recurrence. There is a lack of methods to diagnose MVI preoperatively. The objective of this study was to develop a model for preoperative prediction of MVI in HCC.
methodThe training cohort data were obtained from our previous study. One hundred and fourteen liver transplant patients with HCC were enrolled for validation. The serum level of soluble tumor necrosis factor receptor-2 (sTNFR2) was detected by ELISA. The Kaplan-Meier method was used for survival analysis. The multivariate logistic regression analysis was used to identify independent predictors of MVI, and a nomogram was constructed for visualization.
resultThe recipients with MVI had significantly poorer outcomes than those without MVI both in the training cohort (n = 83, P < 0.001) and the validation cohort (P < 0.001). The inflammatory profiling from the training cohort data indicated that the serum level of B-cell activating factor (P = 0.014) and sTNFR2 (P = 0.013) significantly elevated, and the serum level of osteocalcin (P = 0.002) decreased in patients with MVI. Multivariate logistic analysis showed that the Milan criteria and the serum sTNFR2 were independent predictors for the presence of MVI, and a nomogram was constructed. The nomogram demonstrated an area under the receiver operating characteristic curve (AUROC) of 0.821 for MVI and distinct stratification for tumor recurrence (P < 0.001). Furthermore, the data in the validation cohort revealed an acceptable discriminative ability of confirmed MVI (AUROC = 0.702) and a notable discriminating capability for tumor recurrence (P = 0.043).
conclusionThe non-invasive model based on sTNFR2 could effectively predict preoperative MVI in HCC. And the nomogram could discriminate the tumor recurrence risk for HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.